DrugPatentWatch Database Preview

AMERGE Drug Profile

« Back to Dashboard

When do Amerge patents expire, and what generic alternatives are available?

Amerge is a drug marketed by Glaxosmithkline Llc and is included in one NDA.

The generic ingredient in AMERGE is naratriptan hydrochloride. There are six drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the naratriptan hydrochloride profile page.

Summary for AMERGE

US Patents:	0
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	62
Clinical Trials:	4
Patent Applications:	381
Formulation / Manufacturing:	see details
Drug Prices:	see details
DailyMed Link:	AMERGE at DailyMed

Pharmacology for AMERGE

Drug Class	Serotonin-1b and Serotonin-1d Receptor Agonist
Mechanism of Action	Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists

Synonyms for AMERGE

10X8X4P12Z

143388-64-1

1H-Indole -5-ethanesulfonamide,N-methyl-3-(1-methyl-4-piperidinyl)-, monohydrochloride

1H-Indole-5-ethanesulfonamide, N-methyl-3-(1-methyl-4-piperidinyl)-, monohydrochloride

2-[3-(1-methyl-piperidin-4-yl)-1H-indol-5-yl]-ethanesulfonic acid methylamide Hydrochloride

388N641

A808063

AB0033380

ABP001029

AC-5014

AC1L1U3C

AC1Q3ETY

AK398843

AKOS005145806

Amerge (TN)

AN-5269

API0000686

AT-19354

AWEZYKMQFAUBTD-UHFFFAOYSA-N

C17H25N3O2S.HCl

CAS-143388-64-1

CCG-221770

CHEBI:7479

CHEMBL1200601

CS-2132

CTK8E8530

D00674

DSSTox_CID_28990

DSSTox_GSID_49064

DSSTox_RID_83255

DTXSID6049064

FT-0672649

GG-548

GR 85548A

GR-85548A

HY-B0197A

J-007804

KS-00000OQE

LS-172502

MFCD08141821

MLS006010726

MolPort-003-849-333

N-methyl-2-(3-(1-methylpiperidin-4-yl)-1H-indol-5-yl)ethanesulfonamide hydrochloride

N-methyl-2-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]ethanesulfonamide hydrochloride

N-Methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]ethanesulfonamide Hydrochloride

N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide hydrochloride

N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide;hydrochloride

N-Methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulfonamide hydrochloride

n-methyl-3-(1-methyl-4-piperidinyl)-1h-indole-5-ethanesulphonamide hydrochloride

N-Methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulphonamide, hydrochloride

N-Methyl-3-(1-methyl-4-piperidyl)indole-5-ethanesulfonamide monohydrochloride

Naramig

Naratriptan (hydrochloride)

Naratriptan HCl

NARATRIPTAN HYDROCHLORIDE

Naratriptan hydrochloride (JAN/USAN)

Naratriptan hydrochloride [USAN:USP]

Naratriptan hydrochloride [USAN]

Naratriptan hydrochloride, >=98% (HPLC)

Naratriptan hydrochloride, United States Pharmacopeia (USP) Reference Standard

naratriptanhydrochloride

NCGC00181786-01

NCGC00181786-02

NCGC00261151-01

PubChem16865

Q-201448

QCR-255

RB3224

RTC-070946

s1488

SCHEMBL41527

SMR002529694

TC-070946

Tox21_113617

Tox21_113617_1

Tox21_500466

UNII-10X8X4P12Z

VA11356

X6918

US Patents and Regulatory Information for AMERGE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline Llc	AMERGE	naratriptan hydrochloride	TABLET;ORAL	020763-002	Feb 10, 1998	AB	RX	Yes	No
Glaxosmithkline Llc	AMERGE	naratriptan hydrochloride	TABLET;ORAL	020763-001	Feb 10, 1998	AB	RX	Yes	Yes

Expired US Patents for AMERGE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline Llc	AMERGE	naratriptan hydrochloride	TABLET;ORAL	020763-002	Feb 10, 1998
Glaxosmithkline Llc	AMERGE	naratriptan hydrochloride	TABLET;ORAL	020763-001	Feb 10, 1998